- Home
- ALLO vs HRTX Comparison
ALLO vs HRTX Comparison
Compare ALLO & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- HRTX
- Stock Information
- Founded
- ALLO 2017
- HRTX 1983
- Country
- ALLO United States
- HRTX United States
- Employees
- ALLO N/A
- HRTX N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- HRTX Health Care
- Exchange
- ALLO Nasdaq
- HRTX Nasdaq
- Market Cap
- ALLO 277.8M
- HRTX 325.0M
- IPO Year
- ALLO 2018
- HRTX 1987
- Fundamental
- Price
- ALLO $1.21
- HRTX $2.20
- Analyst Decision
- ALLO Strong Buy
- HRTX Strong Buy
- Analyst Count
- ALLO 9
- HRTX 2
- Target Price
- ALLO $8.44
- HRTX $5.00
- AVG Volume (30 Days)
- ALLO 2.5M
- HRTX 1.6M
- Earning Date
- ALLO 08-06-2025
- HRTX 08-05-2025
- Dividend Yield
- ALLO N/A
- HRTX N/A
- EPS Growth
- ALLO N/A
- HRTX N/A
- EPS
- ALLO N/A
- HRTX N/A
- Revenue
- ALLO N/A
- HRTX $148,518,000.00
- Revenue This Year
- ALLO N/A
- HRTX $12.08
- Revenue Next Year
- ALLO $199.63
- HRTX $12.57
- P/E Ratio
- ALLO N/A
- HRTX N/A
- Revenue Growth
- ALLO N/A
- HRTX 12.43
- 52 Week Low
- ALLO $0.86
- HRTX $1.04
- 52 Week High
- ALLO $3.78
- HRTX $3.73
- Technical
- Relative Strength Index (RSI)
- ALLO 43.73
- HRTX 59.01
- Support Level
- ALLO $1.11
- HRTX $2.04
- Resistance Level
- ALLO $1.29
- HRTX $2.30
- Average True Range (ATR)
- ALLO 0.09
- HRTX 0.13
- MACD
- ALLO -0.01
- HRTX 0.01
- Stochastic Oscillator
- ALLO 25.81
- HRTX 75.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.